Lyell Immunopharma, Inc. Common Stock LYEL
i
Market dataready · fetched 2026-11-12T03:57:10.839Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T21:00:02.073174235Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-12T03:57:10.440647+00:00
Lyell Immunopharma, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 11.83 | 533.0% | 44.4% | |||
| 25Δ | 13.42 | 432.2% | 34.9% | |||
| 30Δ | 14.69 | 358.3% | 27.4% | |||
| 35Δ | 15.69 | 302.6% | 21.4% | |||
| 40Δ | 26.69 | 476.8% | 72.8% | 16.47 | 259.4% | 16.8% |
| 45Δ | 21.59 | 379.3% | 42.6% | 17.14 | 224.4% | 13.0% |
| 50Δ | 18.93 | 309.4% | 26.8% | 17.69 | 201.0% | 10.4% |
| 55Δ | 17.42 | 257.7% | 17.8% | 18.15 | 182.1% | 8.5% |
| 60Δ | 16.46 | 226.5% | 12.8% | 18.50 | 169.3% | 7.5% |
| 65Δ | 18.84 | 156.4% | 6.5% | |||
| 70Δ | 19.19 | 143.5% | 5.4% | |||
| 75Δ | 14.86 | 145.3% | 4.0% | 19.54 | 130.7% | 4.4% |
| 80Δ | 14.44 | 135.6% | 2.9% | 19.88 | 117.8% | 3.4% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 11.83
- IV
- 533.0%
- B/E move
- 44.4%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 13.42
- IV
- 432.2%
- B/E move
- 34.9%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 14.69
- IV
- 358.3%
- B/E move
- 27.4%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 15.69
- IV
- 302.6%
- B/E move
- 21.4%
40Δ
- Pseudo strike
- 26.69
- IV
- 476.8%
- B/E move
- 72.8%
- Pseudo strike
- 16.47
- IV
- 259.4%
- B/E move
- 16.8%
45Δ
- Pseudo strike
- 21.59
- IV
- 379.3%
- B/E move
- 42.6%
- Pseudo strike
- 17.14
- IV
- 224.4%
- B/E move
- 13.0%
50Δ
- Pseudo strike
- 18.93
- IV
- 309.4%
- B/E move
- 26.8%
- Pseudo strike
- 17.69
- IV
- 201.0%
- B/E move
- 10.4%
55Δ
- Pseudo strike
- 17.42
- IV
- 257.7%
- B/E move
- 17.8%
- Pseudo strike
- 18.15
- IV
- 182.1%
- B/E move
- 8.5%
60Δ
- Pseudo strike
- 16.46
- IV
- 226.5%
- B/E move
- 12.8%
- Pseudo strike
- 18.50
- IV
- 169.3%
- B/E move
- 7.5%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 18.84
- IV
- 156.4%
- B/E move
- 6.5%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 19.19
- IV
- 143.5%
- B/E move
- 5.4%
75Δ
- Pseudo strike
- 14.86
- IV
- 145.3%
- B/E move
- 4.0%
- Pseudo strike
- 19.54
- IV
- 130.7%
- B/E move
- 4.4%
80Δ
- Pseudo strike
- 14.44
- IV
- 135.6%
- B/E move
- 2.9%
- Pseudo strike
- 19.88
- IV
- 117.8%
- B/E move
- 3.4%
Options history
Table
| Date | IV (%) |
|---|---|
| 177.51% | |
| 183.33% | |
| 222.19% | |
| 211.85% | |
| 229.13% | |
| 110.84% | |
| 115.80% | |
| 116.21% | |
| 113.81% | |
| 112.81% | |
| 126.31% | |
| 131.25% | |
| 131.85% | |
| 130.42% | |
| 137.62% | |
| 139.30% | |
| 162.01% | |
| 160.79% | |
| 175.88% | |
| 205.89% | |
| 255.06% | |
| 153.99% | |
| 157.95% | |
| 157.61% | |
| 176.65% | |
| 183.85% | |
| 191.93% | |
| 204.72% | |
| 211.84% | |
| 210.50% | |
| 227.78% | |
| 295.88% | |
| 289.51% | |
| 176.75% |
Biotechnology
MANE
Description unavailable
More →MAZE
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic…
More →MBX
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and…
More →MCRB
Seres Therapeutics, Inc., a microbiome therapeutic platform company, is involved in the development of bacterial consortia that are designed to functionally interact with host…
More →MDGL
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of…
More →MDWD
MediWound Ltd., a biopharmaceutical company, develops, manufactures and markets new and biotherapeutic solutions for tissue repair and regeneration. The company is headquartered…
More →